PUBLISHER: Grand View Research | PRODUCT CODE: 2017716
PUBLISHER: Grand View Research | PRODUCT CODE: 2017716
The global sterile injectables CDMO market size was estimated at USD 37.82 billion in 2025 and is projected to reach USD 87.34 billion by 2033, growing at a CAGR of 11.2% from 2026 to 2033. The market growth is driven by increasing drug development activities of biologics, biosimilars, and personalized medicines, drug approval processes, increasing complexity of therapeutics, and rising need for precise analytical validation and regulatory compliance.
In addition, the increasing number of clinical trials, rising outsourcing of research activities by pharmaceutical and biotechnology companies to specialized contract research organizations (CROs), and ongoing technological advancements are further anticipated to fuel market growth. Furthermore, stringent regulatory requirements, expanding R&D investments, particularly in the emerging markets, and the growing emphasis on biomarker analysis and pharmacokinetic studies are expected to further accelerate market expansion.
The increasing demand for cellular and genetic therapies is driving the market's growth. With the expansion of therapy pipelines, there is a rising requirement for specialized manufacturing capabilities provided by contract manufacturing organizations (CMOs). For instance, according to ClinicalTrials.gov, as of March 2024, over 581 clinical trials were focused on cell therapies and related approaches for treating various diseases in North America is anticipated to drive an increase in contract manufacturing throughout the projected period.
Growth in markets of biosimilars, biologics, personalized medicine, orphan drugs, companion diagnostics, and adaptive trial designs, among others, is anticipated to boost the demand for sterile injectables CDMO. This surge is fueled by the high demand for biologics, complex manufacturing requirements, and regulatory support, which necessitate outsourcing to specialized CDMOs. These organizations provide the required expertise, infrastructure, and scalable manufacturing solutions that pharmaceutical companies need to reduce costs and accelerate time-to-market. Moreover, several companies are investigating new avenues, and the growing requirement to adhere to regulations is driving the demand for specialized service providers with proficiency in sterile injectables contract development and manufacturing affairs.
Furthermore, key initiatives undertaken by the companies in this sector are also expected to boost the market's growth. For instance, in October 2025, Simtra BioPharma Solutions, a specialized CDMO focused on sterile injectable manufacturing, is advancing a two-continent expansion plan aimed at addressing rising global demand for complex, high-value therapies. Following its transition to an independent organization in 2023, the company has intensified investments across North America and Europe, strengthening its manufacturing footprint and expanding advanced capabilities. This strategic growth initiative underscores Simtra's commitment to enhancing capacity, supporting customer pipelines, and delivering scalable, high-quality sterile solutions across key pharmaceutical markets.
The surge in global Alzheimer's disease cases, rising demand for cutting-edge gene therapies, a growing incidence of neurodegenerative diseases, and an increase in genetic disorders collectively propel the expansion of advanced therapies. A substantial number of major and small biotechnology companies are driving innovation in this field in terms of technology and manufacturing capabilities, thereby offering commercial opportunities for market expansion. Furthermore, the recent approval of new products in this market has further accelerated R&D activities in this marketplace.
Global Sterile Injectables CDMO Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global sterile injectables CDMO market report based on molecule type, product, service, therapeutic area, route of administration, end-use, and region.